Evaluation of the Cell Detachment Ratio on pH-responsive Chitosan as a Prognostic Factor in Lung Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04218188

Enrollment

120

Registered

2020-01-06

Start date

2020-01-05

Completion date

2022-12-01

Last updated

2020-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Decision-Making, Early Detection of Cancer

Keywords

pH-responsive chitosan, Cancer stem-like cell, Cell detachment ratio, Prognostic factor

Brief summary

Biomaterial-based cell culture models have been gaining increasing attention as potential therapeutic strategies. The purpose of this project is to evaluate whether the cell detachment ratio on pH-responsive chitosan could be correlated with the overall survival in lung cancer patients. Through controllable cell-material interaction, this project has the intention to develop an alternative tool for both early diagnosis and accurate prognosis in cancer therapeutics.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Lung cancer patient between 20-70 years old who need surgery for the resection of lung lesions. * Willing to sign the consent form under the informed consent.

Exclusion criteria

* Vulnerable subjects included minors, prisoners, aborigines, pregnant women, people with mental disorders, students, and subordinates, etc.

Design outcomes

Primary

Measure	Time frame	Description
The correlation between the cell detachment ratio and the overall survival	5-year follow-up after tumor resection	The purpose of this project is to evaluate whether the cell detachment ratio on pH-responsive chitosan could be correlated with the overall survival in lung cancer patients, hence serve as a prognostic factor for therapeutic strategies. The patient's information required for meta-analysis will be retrieved from medical records, and the log-term follow-up will be conducted.

Secondary

Measure	Time frame	Description
The analyses of the detached cells by specific markers	About one week	The isolated and purified patient-derived tumor cells will be characterized by the expression of surface markers using flow cytometry.

Countries

Taiwan

Contacts

Primary ContactKe-Cheng Chen, M.D., Ph.D.

cskchen@gmail.com886-2-2312-3456

Backup ContactChia-Hsiang Yen, PhD student

f04548042@ntu.edu.tw886-2-23123456

Outcome results